NASDAQ:LGVN Longeveron (LGVN) Stock Price, News & Analysis $1.64 +0.02 (+0.93%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.63 -0.01 (-0.31%) As of 08/1/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Longeveron Stock (NASDAQ:LGVN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Longeveron alerts:Sign Up Key Stats Today's Range$1.55▼$1.6550-Day Range$1.15▼$1.7452-Week Range$1.14▼$3.04Volume119,480 shsAverage Volume831,428 shsMarket Capitalization$24.41 millionP/E RatioN/ADividend YieldN/APrice Target$8.67Consensus RatingBuy Company Overview Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida. Read More Longeveron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreLGVN MarketRank™: Longeveron scored higher than 46% of companies evaluated by MarketBeat, and ranked 632nd out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingLongeveron has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLongeveron has received no research coverage in the past 90 days.Read more about Longeveron's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Longeveron are expected to grow in the coming year, from ($3.69) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Longeveron is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Longeveron is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLongeveron has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Longeveron's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.20% of the float of Longeveron has been sold short.Short Interest Ratio / Days to CoverLongeveron has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Longeveron has recently increased by 58.45%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLongeveron does not currently pay a dividend.Dividend GrowthLongeveron does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.20% of the float of Longeveron has been sold short.Short Interest Ratio / Days to CoverLongeveron has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Longeveron has recently increased by 58.45%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News SentimentN/A News SentimentLongeveron has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Longeveron this week, compared to 1 article on an average week.Search Interest8 people have searched for LGVN on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows2 people have added Longeveron to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Longeveron insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,740.00 in company stock.Percentage Held by Insiders11.20% of the stock of Longeveron is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.01% of the stock of Longeveron is held by institutions.Read more about Longeveron's insider trading history. Receive LGVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter. Email Address LGVN Stock News HeadlinesLongeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular DiseaseJuly 21, 2025 | globenewswire.comLongeveron receives FDA approval for pediatric heart therapy INDJuly 10, 2025 | uk.investing.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 2 at 2:00 AM | Brownstone Research (Ad)Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric ... - Seeking AlphaJuly 10, 2025 | seekingalpha.comLongeveron Inc. Receives FDA Approval for IND Application to Advance Clinical Trial of Stem Cell Therapy for Pediatric Dilated Cardiomyopathy - NasdaqJuly 10, 2025 | nasdaq.comLongeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)July 9, 2025 | finanznachrichten.deLongeveron stock soars after FDA approves IND for heart failure treatmentJuly 9, 2025 | in.investing.comLGVN Announces Groundbreaking Treatment Approved for TrialJuly 9, 2025 | msn.comSee More Headlines LGVN Stock Analysis - Frequently Asked Questions How have LGVN shares performed this year? Longeveron's stock was trading at $1.73 at the beginning of 2025. Since then, LGVN stock has decreased by 5.5% and is now trading at $1.6350. How were Longeveron's earnings last quarter? Longeveron Inc. (NASDAQ:LGVN) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.19. The firm had revenue of $0.77 million for the quarter, compared to analysts' expectations of $0.34 million. Longeveron had a negative trailing twelve-month return on equity of 85.07% and a negative net margin of 760.72%. Read the conference call transcript. When did Longeveron's stock split? Longeveron shares reverse split on the morning of Wednesday, March 27th 2024.The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Longeveron IPO? Longeveron (LGVN) raised $30 million in an initial public offering on Friday, February 12th 2021. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. acted as the underwriters for the IPO. How do I buy shares of Longeveron? Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Longeveron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Longeveron investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN). Company Calendar Last Earnings11/12/2024Today8/02/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LGVN CIK1721484 Webwww.longeveron.com Phone305-302-7158FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Longeveron$8.67 High Price Target$10.00 Low Price Target$6.00 Potential Upside/Downside+430.1%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($6.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$15.97 million Net Margins-760.72% Pretax Margin-760.72% Return on Equity-85.07% Return on Assets-70.74% Debt Debt-to-Equity RatioN/A Current Ratio5.61 Quick Ratio5.61 Sales & Book Value Annual Sales$2.39 million Price / Sales10.21 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book1.11Miscellaneous Outstanding Shares14,930,000Free Float13,256,000Market Cap$24.41 million OptionableNot Optionable Beta0.23 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:LGVN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.